Candida auris: Epidemiology and Antifungal Strategy

Literature Cited

1. 1.

   Satoh K, Makimura K, Hasumi Y, et al. 2009.. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. . Microbiol. Immunol. 53::41–44
   [Google Scholar]
2. 2.

   Chowdhary A, Sharma C, Duggal S, et al. 2013.. New clonal strain of Candidaauris, Delhi, India. . Emerg. Infect. Dis. 19::1670–73
   [Google Scholar]
3. 3.

   Lee WG, Shin JH, Uh Y, et al. 2011.. First three reported cases of nosocomial fungemia caused by Candida auris. . J. Clin. Microbiol. 49::3139–42
   [Google Scholar]
4. 4.

   Magobo RE, Corcoran C, Seetharam S, Govender NP. 2014.. Candida auris–associated candidemia, South Africa. . Emerg. Infect. Dis. 20::1250–52
   [Google Scholar]
5. 5.

   Calvo B, Melo AS, Perozo-Mena A, et al. 2016.. First report of Candida auris in America: clinical and microbiological aspects of 18 episodes of candidemia. . J. Infect. 73::369–74
   [Google Scholar]
6. 6.

   Chowdhary A, Sharma C, Meis JF. 2017.. Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. . PLOS Pathog. 13::e1006290
   [Google Scholar]
7. 7.

   Lockhart SR, Etienne KA, Vallabhaneni S, et al. 2017.. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. . Clin. Infect. Dis. 64::134–40
   [Google Scholar]
8. 8.

   Spruijtenburg B, Badali H, Abastabar M, et al. 2022.. Confirmation of fifth Candida auris clade by whole genome sequencing. . Emerg. Microbes Infect. 11::2405–11
   [Google Scholar]
9. 9.

   Vallabhaneni S, Kallen A, Tsay S, et al. 2016.. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus—United States, May 2013–August 2016. . Morb. Mortal. Wkly. Rep. 65::1234–37
   [Google Scholar]
10. 10.

    Chow NA, Gade L, Tsay SV, et al. 2018.. Multiple introductions and subsequent transmission of multidrug-resistant Candida auris in the USA: a molecular epidemiological survey. . Lancet Infect. Dis. 18::1377–84
    [Google Scholar]
11. 11.

    Eyre DW, Sheppard AE, Madder H, et al. 2018.. A Candida auris outbreak and its control in an intensive care setting. . N. Engl. J. Med. 379::1322–31
    [Google Scholar]
12. 12.

    Schelenz S, Hagen F, Rhodes JL, et al. 2016.. First hospital outbreak of the globally emerging Candida auris in a European hospital. . Antimicrob. Resist. Infect. Control 5::35
    [Google Scholar]
13. 13.

    Borman AM, Szekely A, Johnson EM. 2016.. Comparative pathogenicity of United Kingdom isolates of the emerging pathogen Candida auris and other key pathogenic Candida species. . mSphere 1::e00189
    [Google Scholar]
14. 14.

    Chowdhary A, Kumar VA, Sharma C, et al. 2014.. Multidrug-resistant endemic clonal strain of Candida auris in India. . Eur. J. Clin. Microbiol. Infect. Dis. 33::919–26
    [Google Scholar]
15. 15.

    Kumar J, Eilertson B, Cadnum JL, et al. 2019.. Environmental contamination with Candida species in multiple hospitals including a tertiary care hospital with a Candida auris outbreak. . Pathog. Immun. 4::260–70
    [Google Scholar]
16. 16.

    Adams E, Quinn M, Tsay S, et al. 2018.. Candida auris in healthcare facilities, New York, USA, 2013–2017. . Emerg. Infect. Dis. 24::1816–24
    [Google Scholar]
17. 17.

    Biswal M, Rudramurthy SM, Jain N, et al. 2017.. Controlling a possible outbreak of Candida auris infection: lessons learnt from multiple interventions. . J. Hosp. Infect. 97::363–70
    [Google Scholar]
18. 18.

    Welsh RM, Bentz ML, Shams A, et al. 2017.. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface. . J. Clin. Microbiol. 55::2996–3005
    [Google Scholar]
19. 19.

    Cadnum JL, Shaikh AA, Piedrahita CT, et al. 2017.. Effectiveness of disinfectants against Candida auris and other Candida species. . Infect. Control Hosp. Epidemiol. 38::1240–43
    [Google Scholar]
20. 20.

    Johnson CJ, Eix EF, Lam BC, et al. 2021.. Augmenting the activity of chlorhexidine for decolonization of Candida auris from porcine skin. . J. Fungi 7::804
    [Google Scholar]
21. 21.

    Sherry L, Ramage G, Kean R, et al. 2017.. Biofilm-forming capability of highly virulent, multidrug-resistant Candida auris. . Emerg. Infect. Dis. J. 23::328–31
    [Google Scholar]
22. 22.

    Abdolrasouli A, Armstrong-James D, Ryan L, Schelenz S. 2017.. In vitro efficacy of disinfectants utilised for skin decolonisation and environmental decontamination during a hospital outbreak with Candida auris. . Mycoses 60::758–63
    [Google Scholar]
23. 23.

    Proctor DM, Dangana T, Sexton DJ, et al. 2021.. Integrated genomic, epidemiologic investigation of Candida auris skin colonization in a skilled nursing facility. . Nat. Med. 27::1401–9
    [Google Scholar]
24. 24.

    Tsay S, Kallen A, Jackson BR, et al. 2018.. Approach to the investigation and management of patients with Candida auris, an emerging multidrug-resistant yeast. . Clin. Infect. Dis. 66::306–11
    [Google Scholar]
25. 25.

    Armstrong PA, Rivera SM, Escandon P, et al. 2019.. Hospital-associated multicenter outbreak of emerging fungus Candida auris, Colombia, 2016. . Emerg. Infect. Dis. 25::1339–46
    [Google Scholar]
26. 26.

    Morales-López SE, Parra-Giraldo CM, Ceballos-Garzón A, et al. 2017.. Invasive infections with multidrug-resistant yeast Candida auris, Colombia. . Emerg. Infect. Dis. 23::162–64
    [Google Scholar]
27. 27.

    Khatamzas E, Madder H, Jeffery K. 2019.. Neurosurgical device–associated infections due to Candida auris—three cases from a single tertiary center. . J. Infect. 78::409–21
    [Google Scholar]
28. 28.

    Shastri PS, Shankarnarayan SA, Oberoi J, et al. 2020.. Candida auris candidaemia in an intensive care unit—prospective observational study to evaluate epidemiology, risk factors, and outcome. . J. Crit. Care 57::42–48
    [Google Scholar]
29. 29.

    Park JY, Bradley N, Brooks S, et al. 2019.. Management of patients with Candida auris fungemia at Community Hospital, Brooklyn, New York, USA, 2016–2018. . Emerg. Infect. Dis. J. 25::601–2
    [Google Scholar]
30. 30.

    Sayeed MA, Farooqi J, Jabeen K, Mahmood SF. 2019.. Comparison of risk factors and outcomes of Candida auris candidemia with non–Candida auris candidemia: a retrospective study from Pakistan. . Med. Mycol. 58::721–29
    [Google Scholar]
31. 31.

    Ruiz-Gaitán A, Moret AM, Tasias-Pitarch M, et al. 2018.. An outbreak due to Candida auris with prolonged colonisation and candidaemia in a tertiary care European hospital. . Mycoses 61::498–505
    [Google Scholar]
32. 32.

    Chakrabarti A, Sood P, Rudramurthy SM, et al. 2015.. Incidence, characteristics and outcome of ICU-acquired candidemia in India. . Intensive Care Med. 41::285–95
    [Google Scholar]
33. 33.

    Chen J, Tian S, Han X, et al. 2020.. Is the superbug fungus really so scary? A systematic review and meta-analysis of global epidemiology and mortality of Candida auris. . BMC Infect. Dis. 20::827
    [Google Scholar]
34. 34.

    Lone SA, Ahmad A. 2019.. Candida auris—the growing menace to global health. . Mycoses 62::620–37
    [Google Scholar]
35. 35.

    Benedict K, Forsberg K, Gold JAW, et al. 2023.. Candida auris–associated hospitalizations, United States, 2017–2022. . Emerg. Infect. Dis. J. 29::1485–87
    [Google Scholar]
36. 36.

    Huang X, Welsh RM, Deming C, et al. 2021.. Skin metagenomic sequence analysis of early Candida auris outbreaks in U.S. nursing homes. . mSphere 6::e00287
    [Google Scholar]
37. 37.

    Zhu Y, O'Brien B, Leach L, et al. 2020.. Laboratory analysis of an outbreak of Candida auris in New York from 2016 to 2018: impact and lessons learned. . J. Clin. Microbiol. 58::e01503
    [Google Scholar]
38. 38.

    Casadevall A, Kontoyiannis DP, Robert V. 2019.. On the emergence of Candida auris: climate change, azoles, swamps, and birds. . mBio 10::e01397
    [Google Scholar]
39. 39.

    Arora P, Singh P, Wang Y, et al. 2021.. Environmental isolation of Candida auris from the coastal wetlands of Andaman Islands, India. . mBio 12::e03181
    [Google Scholar]
40. 40.

    Akinbobola A, Kean R, Quilliam RS. 2024.. Plastic pollution as a novel reservoir for the environmental survival of the drug resistant fungal pathogen Candida auris. . Mar. Pollut. Bull. 198::115841
    [Google Scholar]
41. 41.

    Babler K, Sharkey M, Arenas S, et al. 2023.. Detection of the clinically persistent, pathogenic yeast spp. Candida auris from hospital and municipal wastewater in Miami–Dade County, Florida. . Sci. Total Environ. 898::165459
    [Google Scholar]
42. 42.

    Barber C, Crank K, Papp K, et al. 2023.. Community-scale wastewater surveillance of Candida auris during an ongoing outbreak in southern Nevada. . Environ. Sci. Technol. 57::1755–63
    [Google Scholar]
43. 43.

    Lyman M, Forsberg K, Sexton DJ, et al. 2023.. Worsening spread of Candida auris in the United States, 2019 to 2021. . Ann. Intern. Med. 176::489–95
    [Google Scholar]
44. 44.

    Koleri J, Petkar HM, Al Soub HARS, Al Maslamani MARS. 2023.. Candida auris blood stream infection—a descriptive study from Qatar. . BMC Infect. Dis. 23::513
    [Google Scholar]
45. 45.

    Bruno VM, Kalachikov S, Subaran R, et al. 2006.. Control of the C. albicans cell wall damage response by transcriptional regulator Cas5. . PLOS Pathog. 2::e21
    [Google Scholar]
46. 46.

    Kordalewska M, Lee A, Park S, et al. 2018.. Understanding echinocandin resistance in the emerging pathogen Candida auris. . Antimicrob. Agents Chemother. 62::e00238
    [Google Scholar]
47. 47.

    Ostrowsky B, Greenko J, Adams E, et al. 2020.. Candida auris isolates resistant to three classes of antifungal medications—New York, 2019. . Morb. Mortal. Wkly. Rep. 69::6–9
    [Google Scholar]
48. 48.

    Maphanga TG, Naicker SD, Kwenda S, et al. 2021.. In vitro antifungal resistance of Candida auris isolates from bloodstream infections, South Africa. . Antimicrob. Agents Chemother. 65::e0051721
    [Google Scholar]
49. 49.

    Pappas PG, Kauffman CA, Andes DR, et al. 2016.. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. . Clin. Infect. Dis. 62::e1–50
    [Google Scholar]
50. 50.

    Govender NP, Avenant T, Brink A, et al. 2019.. Federation of Infectious Diseases Societies of Southern Africa guideline: recommendations for the detection, management and prevention of healthcare-associated Candida auris colonisation and disease in South Africa. . S. Afr. J. Infect. Dis. 34::163
    [Google Scholar]
51. 51.

    Ong CW, Chen SC, Clark JE, et al. 2019.. Diagnosis, management and prevention of Candida auris in hospitals: position statement of the Australasian Society for Infectious Diseases. . Intern. Med. J. 49::1229–43
    [Google Scholar]
52. 52.

    Lepak AJ, Zhao M, Berkow EL, et al. 2017.. Pharmacodynamic optimization for treatment of invasive Candida auris infection. . Antimicrob. Agents Chemother. 61::e00791
    [Google Scholar]
53. 53.

    Grant VC, Nguyen K, Rodriguez S, et al. 2022.. Characterizing safety and clinical outcomes associated with high-dose micafungin utilization in patients with proven invasive candidiasis. . Trop. Med. Infect. Dis. 7::23
    [Google Scholar]
54. 54.

    Chowdhary A, Tarai B, Singh A, Sharma A. 2020.. Multidrug-resistant Candida auris infections in critically ill coronavirus disease patients, India, April–July 2020. . Emerg. Infect. Dis. 26::2694–96
    [Google Scholar]
55. 55.

    Lepak AJ, Zhao M, Andes DR. 2018.. Pharmacodynamic evaluation of rezafungin (CD101) against Candida auris in the neutropenic mouse invasive candidiasis model. . Antimicrob. Agents Chemother. 62::e01572
    [Google Scholar]
56. 56.

    Arendrup MC, Chowdhary A, Astvad KMT, Jørgensen KM. 2018.. APX001A in vitro activity against contemporary blood isolates and Candida auris determined by the EUCAST reference method. . Antimicrob. Agents Chemother. 62::e01225
    [Google Scholar]
57. 57.

    Alvarado-Socarras JL, Vargas-Soler JA, Franco-Paredes C, et al. 2021.. A cluster of neonatal infections caused by Candida auris at a large referral center in Colombia. . J. Pediatr. Infect. Dis. Soc. 10::549–55
    [Google Scholar]
58. 58.

    O'Brien B, Chaturvedi S, Chaturvedi V. 2020.. In vitro evaluation of antifungal drug combinations against multidrug-resistant Candida auris isolates from New York outbreak. . Antimicrob. Agents Chemother. 64::e02195
    [Google Scholar]
59. 59.

    Caballero U, Eraso E, Quindos G, et al. 2023.. PK/PD modeling and simulation of the in vitro activity of the combinations of isavuconazole with echinocandins against Candida auris. . CPT Pharmacomet. Syst. Pharmacol. 12::770–82
    [Google Scholar]
60. 60.

    Caballero U, Eraso E, Quindos G, Jauregizar N. 2021.. In vitro interaction and killing-kinetics of amphotericin B combined with anidulafungin or caspofungin against Candida auris. . Pharmaceutics 13::1333
    [Google Scholar]
61. 61.

    Fakhim H, Chowdhary A, Prakash A, et al. 2017.. In vitro interactions of echinocandins with triazoles against multidrug-resistant Candida auris. . Antimicrob. Agents Chemother. 61::e01056
    [Google Scholar]
62. 62.

    Bidaud AL, Botterel F, Chowdhary A, Dannaoui E. 2019.. In vitro antifungal combination of flucytosine with amphotericin B, voriconazole, or micafungin against Candida auris shows no antagonism. . Antimicrob. Agents Chemother. 63::e01393
    [Google Scholar]
63. 63.

    Ruiz-Gaitán A, Martínez H, Moret AM, et al. 2019.. Detection and treatment of Candida auris in an outbreak situation: risk factors for developing colonization and candidemia by this new species in critically ill patients. . Expert Rev. Anti-Infect. Ther. 17::295–305
    [Google Scholar]
64. 64.

    Ashkenazi-Hoffnung L, Rosenberg Danziger C. 2023.. Navigating the new reality: a review of the epidemiological, clinical, and microbiological characteristics of Candida auris, with a focus on children. . J. Fungi 9::176
    [Google Scholar]
65. 65.

    Watanabe NA, Miyazaki M, Horii T, et al. 2012.. E1210, a new broad-spectrum antifungal, suppresses Candida albicans hyphal growth through inhibition of glycosylphosphatidylinositol biosynthesis. . Antimicrob. Agents Chemother. 56::960–71
    [Google Scholar]
66. 66.

    Vazquez JA, Pappas PG, Boffard K, et al. 2023.. Clinical efficacy and safety of a novel antifungal, fosmanogepix, in patients with candidemia caused by Candida auris: results from a phase 2 trial. . Antimicrob. Agents Chemother. 67::e0141922
    [Google Scholar]
67. 67.

    Simon SP, Li R, Silver M, et al. 2023.. Comparative outcomes of Candida auris bloodstream infections: a multicenter retrospective case–control study. . Clin. Infect. Dis. 76::e1436–43
    [Google Scholar]
68. 68.

    Benedict K, Forsberg K, Gold JAW, et al. 2023.. Candida auris–associated hospitalizations, United States, 2017–2022. . Emerg. Infect. Dis. 29::1485–87
    [Google Scholar]
69. 69.

    Berrio I, Caceres DH, Coronell RW, et al. 2021.. Bloodstream infections with Candida auris among children in Colombia: clinical characteristics and outcomes of 34 cases. . J. Pediatr. Infect. Dis. Soc. 10::151–54
    [Google Scholar]
70. 70.

    Adam RD, Revathi G, Okinda N, et al. 2019.. Analysis of Candida auris fungemia at a single facility in Kenya. . Int. J. Infect. Dis. 85::182–87
    [Google Scholar]
71. 71.

    Kojic EM, Darouiche RO. 2004.. Candida infections of medical devices. . Clin. Microbiol. Rev. 17::255–67
    [Google Scholar]
72. 72.

    Nagy F, Toth Z, Nyikos F, et al. 2021.. In vitro and in vivo interaction of caspofungin with isavuconazole against Candida auris planktonic cells and biofilms. . Med. Mycol. 59::1015–23
    [Google Scholar]